Abstract
Purpose The objective of this study was to evaluate the efficacy and safety of the lercanidipine/valsartan combination compared with lercanidipine monotherapy in patients with hypertension. Methods Part 1 of this study was the randomized, multicenter, double-blind, parallel group, Phase III, 8-week clinical trial to compare superiority of lercanidipine 10 mg/valsartan 80 mg (L10/V80) and lercanidipine 10 mg/valsartan 160 mg (L10/V160) combinations with lercanidipine 10 mg (L10) monotherapy. At screening, hypertensive patients, whose diastolic blood pressure (DBP) was >90 mm Hg after 4 weeks with L10, were randomized to 3 groups of L10, L10/V80, and L10/V160. The primary end point was the change in the mean sitting DBP from baseline (week 0) after 8 weeks of therapy. Patients who were randomly assigned to L10/V160 and whose mean DBP was still ¥.
| Original language | English |
|---|---|
| Pages (from-to) | 1726-1739 |
| Number of pages | 14 |
| Journal | Clinical Therapeutics |
| Volume | 37 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2015 Aug 1 |
Bibliographical note
Publisher Copyright:© 2015 ElsevierHSJournals,Inc.Allrightsreserved.
Keywords
- combination
- hypertension
- lercanidipine
- valsartan
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS